Status:
RECRUITING
Live Birth Rate Between ICSI and AOA and ICSI Alone in Patients With Severe Teratospermia
Lead Sponsor:
ShangHai Ji Ai Genetics & IVF Institute
Conditions:
Male Infertility
Teratospermia
Eligibility:
All Genders
20-37 years
Phase:
NA
Brief Summary
The goal of this clinical trial is to compare the live birth rate between intracytoplasmic sperm injection (ICSI) and artificial oocyte activation (AOA) vs intracytoplasmic sperm injection alone in pa...
Eligibility Criteria
Inclusion
- Age of women 20-37 years at the time of ovarian stimulation for ICSI
- At least three matured oocytes Severe teratozoospermia: defined as abnormal sperm morphology ranging between 99-100%, including globozoospermia and tapered-head.
Exclusion
- Presence of hydrosalpinx which is not surgically treated
- Undergoing preimplantation genetic testing
- Recurrent pregnancy loss (defined as two or more previous spontaneous pregnancy losses)
- Known uterine abnormality (e.g., uterine congenital malformation; untreated uterine septum, adenomyosis, or submucous myoma; endometrial polyps; or intrauterine adhesions)
- Abnormal parental karyotyping, or Medical conditions that assisted reproductive technology or pregnancy is contraindicated
Key Trial Info
Start Date :
August 30 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2026
Estimated Enrollment :
208 Patients enrolled
Trial Details
Trial ID
NCT06561451
Start Date
August 30 2024
End Date
December 30 2026
Last Update
May 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ShangHai JIAI Genetics &I VF Institute
Shanghai, China